Breaking News Instant updates and real-time market news.

TODAY'S FREE FLY STORIES

Recommendations
Ziopharm took 'important step' with start of CAR-T study, says Lake Street » 09:11
07/10/20
07/10
09:11
07/10/20
09:11
ZIOP

Ziopharm

$3.24 /

+0.04 (+1.25%)

Lake Street analyst…

Lake Street analyst Thomas Flaten said a combination of planning issues, manufacturing optimization and the pandemic delayed initiation of Ziopharm's Phase 1 study of its CD19 CAR-T program and he sees the start of the trial as "an important step, while adding that "results will ultimately determine the success of the study." Flaten, who acknowledges that "it will be some time until data is available," keeps a Buy rating and $7 price target on Ziopharm shares.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

  • 05
    Feb
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

Periodicals
Apple Silicon Macs to hit mass production this year, next year, MacRumors says » 09:11
07/10/20
07/10
09:11
07/10/20
09:11
AAPL

Apple

$382.78 /

+1.49 (+0.39%)

Apple Silicon 13.3-inch…

Apple Silicon 13.3-inch MacBook Pro will go into mass production in Q4 and an arm-based MacBook Air will be produced in either in Q4 or in Q1 of next year, Tim Hardwick of MacRumors reports, citing predictions from Apple analyst Ming-Chi Kuo. Kuo believes that Apple intends to launch a mini-LED 16-inch MacBook Pro and a 14.1-inch MacBook Pro, but these will likely arrive in Q2 or Q3 of 2021. Previous rumors suggested an updated 16-inch MacBook Pro could arrive in October or November of this year. Reference Link

ShowHide Related Items >><<
AAPL Apple
$382.78 /

+1.49 (+0.39%)

AAPL Apple
$382.78 /

+1.49 (+0.39%)

07/09/20 Nomura Instinet
Nomura says Apple iPhone shipments in China pressured by 5G models in June
07/08/20 Deutsche Bank
'Nervous' Deutsche Bank raises Apple price target to $400 from $380
07/07/20 Raymond James
Apple price target raised to $400 from $340 at Raymond James
07/06/20 Loop Capital
Apple's build plan update negates speculation of cut, says Loop Capital
AAPL Apple
$382.78 /

+1.49 (+0.39%)

AAPL Apple
$382.78 /

+1.49 (+0.39%)

AAPL Apple
$382.78 /

+1.49 (+0.39%)

AAPL Apple
$382.78 /

+1.49 (+0.39%)

AAPL Apple
$382.78 /

+1.49 (+0.39%)

General news
Today's U.S. June PPI report sharply undershot estimates » 09:10
07/10/20
07/10
09:10
07/10/20
09:10

Today's U.S. June…

Today's U.S. June PPI report sharply undershot estimates with a -0.2% headline drop and a -0.3% core price decline, following a May headline gain of 0.4% despite a -0.1% core price, but big respective April declines of a record -1.3% and -0.3%. The June swings rounded from -0.170% and -0.254% respectively. June weakness reflected a big -5.2% food price drop that offset the expected big 7.7% energy price rise to leave a goods price gain of only 0.2%. The big food price drop reversed May's record-large 6.0% food price spike. Service prices fell -0.3% in June, with divergent component swings in May and June that reversed the opposite divergent swings in March and April. Analysts saw a flat June figure for PPI on the old SOP basis, after a 2.3% May surge that marked the largest gain since August of 1973 with the lifting of price controls for food. Analysts saw a -3.5% record-plunge in April PPI on the SOP basis. The CPI and PPI reports initially showed big downside hits in March and April from declines in aggregate demand, but analysts're now also seeing pockets of upside price disruptions from supply constraints, as evident in May's PPI food price spike that was reversed in June, and the updraft in energy prices with OPEC production cuts. Though the demand-hit from the pandemic again dominated today's headline, analysts should see increasing evidence of supply chain disruptions as analysts proceed through Q3.

General news
U.S. equity futures are weaker » 09:10
07/10/20
07/10
09:10
07/10/20
09:10

U.S. equity futures are…

U.S. equity futures are weaker but have managed to edge up from overnight lows following positive news on the drug remdesivir. Ongoing worries over the resurgence of the virus and the consequent possible stalling of the recovery weighed on sentiment overnight, and will likely be a headwind today. Geopolitical tensions between China and the U.S. are factor, while lower yields are scarring investors. The Dow mini is -0.2% lower, the S&amp;P 500 is off -0.1% and the NASDAQ is -0.08% softer. Stocks are mildly firmer in Europe, with the Euro Stoxx up 0.6%, Germany's DAX 0.7% higher and France's CAC 40 up 0.6%. The UK'S FTSE 100 has increased 0.5%. Asia's stock markets posted losses -- Japan's Nikkei 225 closed with a -1.1% drop, Hong Kong's Hang Seng fell -1.8% and China's CSI 300 declined -1.8% after recent lofty gains.

Hot Stocks
Leaf Group holders issue letter regarding recent call with Independent Committee » 09:09
07/10/20
07/10
09:09
07/10/20
09:09
LEAF

Leaf Group

$3.82 /

-0.01 (-0.26%)

Investors owning over 40%…

Investors owning over 40% of the issued and outstanding shares of Leaf Group issued a letter to the Company's board expressing their concerns and disappointment around a recent call with the two members of the board's Independent Committee as well as the Company's outside counsel. The letter says, "We were disappointed in our perfunctory conversation yesterday with the two members of the so-called Independent Committee of Directors, Deborah Benton and Beverly Carmichael, and the Company's outside counsel, Joe Johnson from Goodwin Procter LLP. This conversation was intended to allow us - owners of 40% of the outstanding stock of the Company - to explain our concerns regarding the performance of the business, the CEO's blatant mismanagement and conflicts, and Leaf's failure to conduct a bona fide strategic alternatives process. Instead, from the start it was clear to us that the Committee had agreed to the call simply to "check the box" of having engaged with us, rather than out of any real desire to listen to the perspectives of a large portion of the Company's shareholders. As owners of 40% of the stock, we are deeply troubled by the performance of the Company and its CEO. On the call, we reiterated our view that the only path to unlock shareholder value is the removal of Sean Moriarty as CEO, refreshing the Board with directors chosen by shareholders and the initiation of a legitimate strategic process to consider the sale of the Company or its Media and Marketplace businesses... We were also surprised that the Committee has rejected the opportunity, as a supposedly independent group of directors, to avail itself of independent, outside advice. Rather, the Committee has elected to use the Company's incumbent counsel, Goodwin Procter, which has long served at the pleasure of the current CEO... The Committee's position relies on the faulty premise that it somehow understands the views of the other 60% of holders and that those other shareholders would wholesale disagree with our perspectives. This mythical 60% of shareholders, we are expected to believe, are pleased with a negative 43% shareholder return over the last year. They are, apparently, satisfied that shareholders have lost 60% of their capital during Mr. Moriarty's tenure as CEO. We doubt that. The Committee told us, effectively, that even though owners of 40% of the Company were gravely concerned about the management and strategic direction of the Company, the Board knows better and is comfortable that the "silent majority" is supportive of a value-destroying CEO and failed strategy. We cannot think of another Board that has been so confident in its views in the face of such significant value destruction and substantial, public shareholder opposition to the status quo... Given the cavalier conduct of the Committee and this Board in response to our concerns about the management and strategy of the Company, we do not believe shareholders should trust the incumbent directors to make critical decisions about the leadership or strategy of the Company or its Board composition. While the Committee admitted there are legitimate concerns regarding the independence of the Board, it appears to believe the Board can be trusted to fix these problems on its own, without shareholder input. To the contrary, we believe that shareholders must be given a direct voice in the composition of the Board and the leadership of the Company. Our conviction on this critical point has only grown, given the dismissive attitude of the Committee toward our legitimate concerns... Rather than seeking a better path forward for the Company - one that could garner the support of our group and other shareholders - the purpose of the Committee appears to be to offer a veneer of credibility to the Board's misguided attempts to retain Leaf's underperforming CEO, defend the failed strategic alternatives process and deflect claims that substantial conflicts of interests involving members of management and the Board have been a disservice to shareholders. With respect to the latter, we call upon the Board to immediately disclose publicly the conflicts of interest of which it is aware that involve Board members and Mr. Moriarty. We believe the Company's shareholder base deserves to know. It was our sincere hope to have a productive dialogue with the Board and the Committee. It appears, however, the Board is only interested in protecting the status quo and is using the so-called Independent Committee as a device to provide the Board a shield. The Board should instead exercise independent business judgment and remove the Company's underperforming CEO, refresh the Board with shareholder input and restart the strategic alternatives process."

ShowHide Related Items >><<
LEAF Leaf Group
$3.82 /

-0.01 (-0.26%)

LEAF Leaf Group
$3.82 /

-0.01 (-0.26%)

08/06/19 Cowen
Leaf Group downgraded to Market Perform at Cowen
08/06/19 Cowen
Leaf Group downgraded to Market Perform from Outperform at Cowen
LEAF Leaf Group
$3.82 /

-0.01 (-0.26%)

Recommendations
Carvana price target raised to $115 from $75 at JPMorgan » 09:08
07/10/20
07/10
09:08
07/10/20
09:08
CVNA

Carvana

$138.59 /

-0.205 (-0.15%)

JPMorgan analyst Rajat…

JPMorgan analyst Rajat Gupta raised the firm's price target on Carvana to $115 from $75 and keeps a Neutral rating on the shares. The company has "hardly put a foot wrong" through the COVID-19 crisis period and has been rewarded with the shares up 51% year-to-date, Gupta tells investors in a research note. The analyst, however, believes Carvana's current valuation gives the company "ample credit" for its long-term volume growth potential.

ShowHide Related Items >><<
CVNA Carvana
$138.59 /

-0.205 (-0.15%)

CVNA Carvana
$138.59 /

-0.205 (-0.15%)

07/08/20 Baird
Carvana price target raised to $148 from $105 at Baird
07/06/20 Wedbush
Carvana price target raised to $125 from $90 at Wedbush
07/06/20 Wedbush
Wedbush bullish on Vroom, initiates with an Outperform
07/06/20 JMP Securities
Carvana price target raised to $155 from $105 at JMP Securities
CVNA Carvana
$138.59 /

-0.205 (-0.15%)

  • 19
    May
CVNA Carvana
$138.59 /

-0.205 (-0.15%)

CVNA Carvana
$138.59 /

-0.205 (-0.15%)

CVNA Carvana
$138.59 /

-0.205 (-0.15%)

Conference/Events
Jefferies consumer analysts to hold an analyst/industry conference call » 09:08
07/10/20
07/10
09:08
07/10/20
09:08

Consumer Analysts provide…

Consumer Analysts provide insight into current consumer trends on an Analyst/Industry conference call to be held on July 10 at 10 am.

Recommendations
JPMorgan has 'increasing conviction' in Disney returning to health » 09:06
07/10/20
07/10
09:06
07/10/20
09:06
DIS

Disney

$116.91 /

+0.24 (+0.21%)

All of Disney's…

All of Disney's parks now have reopening dates set with the exception of Disneyland in Anaheim, JPMorgan analyst Alexia Quadrani tells investors in a research note. The analyst has "increasing conviction that the health of the company is returning throughout several of its segments," with a move toward profitability in fiscal 2023 at Disney+, the reopening of the parks, and the return of live sports. She notes that Disney+ saw a spike in downloads from release of Hamilton. Quadrani keeps an Overweight rating on the shares with a $135 price target.

ShowHide Related Items >><<
DIS Disney
$116.91 /

+0.24 (+0.21%)

DIS Disney
$116.91 /

+0.24 (+0.21%)

07/08/20 Guggenheim
Disney price target raised to $123 from $115 at Guggenheim
06/24/20 Morgan Stanley
Morgan Stanley says time might be right for Disney to move ESPN to streaming
06/19/20 Wells Fargo
Disney price target raised to $118 from $107 at Wells Fargo
06/15/20 BofA
BofA boosts Disney target to $146, sees 'compelling' entry point
DIS Disney
$116.91 /

+0.24 (+0.21%)

DIS Disney
$116.91 /

+0.24 (+0.21%)

DIS Disney
$116.91 /

+0.24 (+0.21%)

DIS Disney
$116.91 /

+0.24 (+0.21%)

On The Fly
Fly Intel: Pre-market Movers » 09:06
07/10/20
07/10
09:06
07/10/20
09:06
GILD

Gilead

$74.67 /

-0.96 (-1.27%)

, ZIOP

Ziopharm

$3.24 /

+0.04 (+1.25%)

, ALV

Autoliv

$63.32 /

-0.9 (-1.40%)

, MATX

Matson

$27.46 /

-0.69 (-2.45%)

, GBX

Greenbrier

$21.75 /

-0.895 (-3.95%)

, SLP

Simulations Plus

$63.55 /

+1.57 (+2.53%)

, BYND

Beyond Meat

$141.13 /

-3.735 (-2.58%)

, SC

Santander Consumer

$17.32 /

-1.005 (-5.48%)

, FSLY

Fastly

$102.67 /

+6.52 (+6.78%)

, RIG

Transocean

$1.90 /

-0.12 (-5.96%)

, CNTG

Centogene

$17.06 /

-2.1 (-10.96%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

CNTG Centogene
$17.06 /

-2.1 (-10.96%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ALV Autoliv
$63.32 /

-0.9 (-1.40%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

07/10/20 Stifel
Galapagos downgraded to Hold from Buy at Stifel
06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ALV Autoliv
$63.32 /

-0.9 (-1.40%)

07/09/20 Goldman Sachs
Autoliv initiated with a Buy at Goldman Sachs
06/19/20 JPMorgan
Autoliv price target raised to $63 from $55 at JPMorgan
06/11/20 Evercore ISI
Autoliv upgraded to In Line from Underperform at Evercore ISI
05/28/20 Wolfe Research
Autoliv downgraded to Peer Perform from Outperform at Wolfe Research
MATX Matson
$27.46 /

-0.69 (-2.45%)

07/10/20 Stifel
Matson price target raised to $44 from $35 at Stifel
04/06/20 Stephens
Matson downgraded to Equal Weight from Overweight at Stephens
02/27/20 Stifel
Matson upgraded to Buy from Hold at Stifel
GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

04/28/20 Susquehanna
Greenbrier downgraded to Negative from Neutral at Susquehanna
04/08/20 KeyBanc
Greenbrier price target lowered to $30 from $38 at KeyBanc
01/14/20 Wells Fargo
Greenbrier downgraded to Underweight from Equal Weight at Wells Fargo
11/08/19 Susquehanna
Greenbrier downgraded to Neutral from Positive at Susquehanna
SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

07/10/20 Craig-Hallum
Simulations Plus price target raised to $75 from $56 at Craig-Hallum
06/08/20 Craig-Hallum
Simulations Plus price target raised to $56 from $40 at Craig-Hallum
01/06/20 Craig-Hallum
Simulations Plus initiated with a Buy at Craig-Hallum
BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

07/10/20 Citi
Citi starts Beyond Meat with Sell, sees 15% share downside
07/10/20 Citi
Beyond Meat initiated with a Sell at Citi
07/09/20 Bernstein
Beyond Meat price target raised to $133 from $118 at Bernstein
06/29/20
Fly Intel: Top five analyst downgrades
SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

06/03/20 Stephens
Stephens says Santander Consumer may benefit if Wells pulling back on auto loans
05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
03/17/20 Barclays
Santander Consumer downgraded to Underweight from Equal Weight at Barclays
01/06/20 Stephens
Stephens upgrades Santander Consumer to Equal Weight ahead of expected buybacks
FSLY Fastly
$102.67 /

+6.52 (+6.78%)

07/10/20 BofA
Fastly double-downgraded to Underperform from Buy at BofA
07/10/20 BofA
Fastly downgraded to Underperform from Buy at BofA
07/09/20 Citi
Citi recommends overweight Zoom Video, underweight Fastly pair trade
07/09/20 Citi
Citi downgraded Fastly to Sell with stock up 400% in three months
RIG Transocean
$1.90 /

-0.12 (-5.96%)

07/08/20 Morgan Stanley
Morgan Stanley downgrades Transocean to Equal Weight on offshore drilling view
07/08/20 Morgan Stanley
Transocean downgraded to Equal Weight from Overweight at Morgan Stanley
07/02/20 Evercore ISI
Transocean secures contract for 20k PSI drillship, says Evercore ISI
06/15/20
Fly Intel: Top five analyst downgrades
CNTG Centogene
$17.06 /

-2.1 (-10.96%)

04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
12/03/19 Baird
Centogene initiated with an Outperform at Baird
12/02/19 BTIG
Centogene initiated with a Buy at BTIG
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ALV Autoliv
$63.32 /

-0.9 (-1.40%)

  • 10
    Jul
  • 21
    May
  • 05
    Feb
  • 07
    Nov
  • 01
    Aug
RIG Transocean
$1.90 /

-0.12 (-5.96%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

CNTG Centogene
$17.06 /

-2.1 (-10.96%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ALV Autoliv
$63.32 /

-0.9 (-1.40%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

Hot Stocks
DBV Technologies publishes results from Phase 3 PEPTITES study » 09:06
07/10/20
07/10
09:06
07/10/20
09:06
DBVT

DBV Technologies

$4.29 /

-0.22 (-4.88%)

DBV Technologies…

DBV Technologies announced that The Journal of Allergy and Clinical Immunology, or JACI, has published results from its three-year, open-label extension of the Phase III PEPITES study, or PEOPLE. The study was published online and will be in an upcoming print edition of the journal. The company said patients demonstrated durable, long-term clinical benefit with an additional two years of treatment with Viaskin Peanut, with low discontinuations due to adverse events. Top-line data from PEOPLE were announced in January and presented with additional detail at the American Academy of Allergy, Asthma & Immunology, or AAAAI. The biologics license application, or BLA, for investigational DBV712 for peanut-allergic children ages four to 11 years is currently under review by the FDA. If approved, DBV712 would be the first once-daily, non-invasive epicutaneous treatment option for children living with peanut allergy. Data from the PEOPLE trial demonstrate that DBV712 was associated with continued response over a three-year treatment period. In the study, 75.9% saw an improvement in eliciting dose, or ED, from baseline to Month 36 and 51.8% achieved an ED of at least 1,000 mg at Month 36. At Month 36, the mean cumulative reactive dose, or CRD, was 1,768.8 mg compared to 223.8 mg at baseline. A treatment effect was seen across the spectrum of baseline sensitivity, including the most sensitive patients; those who entered with an ED of less than or equal to 10 mg saw a 22.5-fold increase in geometric mean ED over the treatment period. Consistent with the high rate of sustained unresponsiveness reported in a previous clinical study, exploratory analyses in a subset of participants showed that 77.8% were able to maintain desensitization, according to predefined study definition, for a two-month period while off therapy and without peanut consumption. A favorable tolerability profile was observed with DBV712 in the PEOPLE trial, consistent with that observed in the clinical program to date in nearly 1,000 participants. The most commonly reported treatment-emergent adverse events, or TEAEs, were application site reactions, which decreased in frequency and severity over time. No treatment-related serious adverse events, or SAEs, were reported. One patient experienced one case of mild anaphylaxis that was determined by the investigator to be possibly related to treatment; it resolved without treatment and the patient continued participation in the study. There was no epinephrine use deemed related to treatment. Treatment compliance remained high throughout PEPITES and PEOPLE at a mean of 98%. Most withdrawals were due to fear or aversion to a double-blind, placebo-controlled food challenge.

ShowHide Related Items >><<
DBVT DBV Technologies
$4.29 /

-0.22 (-4.88%)

DBVT DBV Technologies
$4.29 /

-0.22 (-4.88%)

07/02/20 JMP Securities
JMP Securities positive on DBV Technologies' risk-reward
06/29/20 Citi
DBV approval likely to be delayed beyond action date, says Citi
06/29/20 H.C. Wainwright
DBV Technologies restructuring a proactive step, says H.C. Wainwright
06/26/20 Stifel
DBV restructuring 'not comforting for investors,' says Stifel
DBVT DBV Technologies
$4.29 /

-0.22 (-4.88%)

  • 30
    Jan
  • 09
    Oct
DBVT DBV Technologies
$4.29 /

-0.22 (-4.88%)

Conference/Events
Jefferies technology analyst to hold an analyst/industry conference call » 09:05
07/10/20
07/10
09:05
07/10/20
09:05

Technology Analyst Notter…

Technology Analyst Notter discusses the emerging role of video in public safety communications on an Analyst/Industry conference call to be held on July 10 at 10 am.

Recommendations
Bed Bath & Beyond price target raised to $9 from $5 at Loop Capital » 09:04
07/10/20
07/10
09:04
07/10/20
09:04
BBBY

Bed Bath & Beyond

$7.86 /

-2.54 (-24.42%)

Loop Capital analyst…

Loop Capital analyst Anthony Chukumba raised the firm's price target on Bed Bath & Beyond to $9 from $5 but keeps a Hold rating on the shares after its Q1 earnings. The analyst says the results were worse than expected but he is "not terribly bothered" by the underperformance. Chukumba instead notes that he is "encouraged" by the early results of the reopened stores, the company's "healthy" liquidity position, as well as the progress made by the management on its omnichannel strategy.

ShowHide Related Items >><<
BBBY Bed Bath & Beyond
$7.86 /

-2.54 (-24.42%)

BBBY Bed Bath & Beyond
$7.86 /

-2.54 (-24.42%)

07/07/20 Raymond James
Bed Bath & Beyond price target raised to $13 from $9 at Raymond James
05/26/20 Odeon Capital
Bed Bath & Beyond upgraded to Buy from Hold at Odeon Capital
04/16/20 Loop Capital
Bed Bath & Beyond Q4 results 'less bad than feared' says Loop Capital
04/08/20 Loop Capital
Bed Bath & Beyond price target lowered to $5 from $12 at Loop Capital
BBBY Bed Bath & Beyond
$7.86 /

-2.54 (-24.42%)

BBBY Bed Bath & Beyond
$7.86 /

-2.54 (-24.42%)

BBBY Bed Bath & Beyond
$7.86 /

-2.54 (-24.42%)

BBBY Bed Bath & Beyond
$7.86 /

-2.54 (-24.42%)

Recommendations
Whirlpool price target raised to $158 from $124 at JPMorgan » 09:02
07/10/20
07/10
09:02
07/10/20
09:02
WHR

Whirlpool

$133.21 /

-2.74 (-2.02%)

JPMorgan analyst Michael…

JPMorgan analyst Michael Rehaut raised the firm's price target on Whirlpool to $158 from $124 and keeps an Overweight rating on the shares. Despite a strong rally since late March, the building products sector has not fully recovered its losses from the early days of the pandemic, Rehaut tells investors in a research note. The analyst increased estimates across the group to reflect an improved demand backdrop, "as even lagging subsectors have still likely witnessed monthly improvement."

ShowHide Related Items >><<
WHR Whirlpool
$133.21 /

-2.74 (-2.02%)

WHR Whirlpool
$133.21 /

-2.74 (-2.02%)

06/23/20 Credit Suisse
Whirlpool price target raised to $103 from $90 at Credit Suisse
06/23/20 Deutsche Bank
Whirlpool price target lowered to $109 from $115 at Deutsche Bank
06/15/20 Raymond James
Appliance data points to sequential improvement in demand, says Raymond James
05/27/20 Credit Suisse
Whirlpool initiated with an Underperform at Credit Suisse
WHR Whirlpool
$133.21 /

-2.74 (-2.02%)

WHR Whirlpool
$133.21 /

-2.74 (-2.02%)

WHR Whirlpool
$133.21 /

-2.74 (-2.02%)

WHR Whirlpool
$133.21 /

-2.74 (-2.02%)

Recommendations
Stanley Black & Decker price target raised to $175 from $130 at JPMorgan » 09:02
07/10/20
07/10
09:02
07/10/20
09:02
SWK

Stanley Black & Decker

$136.99 /

-2.4 (-1.72%)

JPMorgan analyst Michael…

JPMorgan analyst Michael Rehaut raised the firm's price target on Stanley Black & Decker to $175 from $130 and keeps an Overweight rating on the shares. Despite a strong rally since late March, the building products sector has not fully recovered its losses from the early days of the pandemic, Rehaut tells investors in a research note. The analyst increased estimates across the group to reflect an improved demand backdrop, "as even lagging subsectors have still likely witnessed monthly improvement."

ShowHide Related Items >><<
SWK Stanley Black & Decker
$136.99 /

-2.4 (-1.72%)

SWK Stanley Black & Decker
$136.99 /

-2.4 (-1.72%)

06/25/20 Wolfe Research
Stanley Black & Decker upgraded to Outperform from Peer Perform at Wolfe Research
06/16/20 Barclays
Stanley Black & Decker price target raised to $150 from $130 at Barclays
06/04/20 Deutsche Bank
Stanley Black & Decker price target raised to $159 from $151 at Deutsche Bank
06/04/20 Credit Suisse
Stanley Black & Decker price target raised to $140 from $125 at Credit Suisse
SWK Stanley Black & Decker
$136.99 /

-2.4 (-1.72%)

SWK Stanley Black & Decker
$136.99 /

-2.4 (-1.72%)

SWK Stanley Black & Decker
$136.99 /

-2.4 (-1.72%)

SWK Stanley Black & Decker
$136.99 /

-2.4 (-1.72%)

Recommendations
PGT Innovations price target raised to $16.50 from $12.50 at JPMorgan » 09:02
07/10/20
07/10
09:02
07/10/20
09:02
PGTI

PGT Innovations

$15.10 /

-0.61 (-3.88%)

JPMorgan analyst Michael…

JPMorgan analyst Michael Rehaut raised the firm's price target on PGT Innovations to $16.50 from $12.50 and keeps a Neutral rating on the shares. Despite a strong rally since late March, the building products sector has not fully recovered its losses from the early days of the pandemic, Rehaut tells investors in a research note. The analyst increased estimates across the group to reflect an improved demand backdrop, "as even lagging subsectors have still likely witnessed monthly improvement."

ShowHide Related Items >><<
PGTI PGT Innovations
$15.10 /

-0.61 (-3.88%)

PGTI PGT Innovations
$15.10 /

-0.61 (-3.88%)

03/17/20 B. Riley FBR
B. Riley FBR downgrades seven Industrials on broadening COVID-19 impact
03/17/20 B. Riley FBR
PGT Innovations downgraded to Neutral from Buy at B. Riley FBR
02/26/20 B. Riley FBR
PGT Innovations price target raised to $20 from $18 at B. Riley FBR
11/08/19 KeyBanc
PGT Innovations downgraded to Sector Weight from Overweight at KeyBanc
PGTI PGT Innovations
$15.10 /

-0.61 (-3.88%)

Periodicals
Intel delays another near-term server project, SemiAccurate reports » 09:02
07/10/20
07/10
09:02
07/10/20
09:02
INTC

Intel

$58.43 /

-0.2 (-0.34%)

Intel is delaying another…

Intel is delaying another near-term server project, SemiAccurate's Charlie Demerjian reports, citing multiple sources. The new delay is not related to any of the previous delays, Demerjian says, and that the new schedule "seems to be tailored to fit public PR statements by key executives rather than being realistic." Reference Link

ShowHide Related Items >><<
INTC Intel
$58.43 /

-0.2 (-0.34%)

INTC Intel
$58.43 /

-0.2 (-0.34%)

07/07/20 William Blair
William Blair says trends helping MaxLinear likely boosting unit being bought
07/06/20
Fly Intel: Top five analyst downgrades
07/06/20 Goldman Sachs
Intel downgraded to Sell from Neutral at Goldman Sachs
06/26/20 KeyBanc
Memory supply remains limited in 2H amid low visibility, says KeyBanc
INTC Intel
$58.43 /

-0.2 (-0.34%)

INTC Intel
$58.43 /

-0.2 (-0.34%)

INTC Intel
$58.43 /

-0.2 (-0.34%)

INTC Intel
$58.43 /

-0.2 (-0.34%)

INTC Intel
$58.43 /

-0.2 (-0.34%)

Recommendations
Owens Corning price target raised to $53 from $37 at JPMorgan » 09:01
07/10/20
07/10
09:01
07/10/20
09:01
OC

Owens Corning

$55.06 /

-1.72 (-3.03%)

JPMorgan analyst Michael…

JPMorgan analyst Michael Rehaut raised the firm's price target on Owens Corning to $53 from $37 and keeps an Underweight rating on the shares. Despite a strong rally since late March, the building products sector has not fully recovered its losses from the early days of the pandemic, Rehaut tells investors in a research note. The analyst increased estimates across the group to reflect an improved demand backdrop, "as even lagging subsectors have still likely witnessed monthly improvement."

ShowHide Related Items >><<
OC Owens Corning
$55.06 /

-1.72 (-3.03%)

OC Owens Corning
$55.06 /

-1.72 (-3.03%)

07/08/20 SunTrust
Owens Corning price target raised to $55 from $45 at SunTrust
06/23/20 Deutsche Bank
Owens Corning price target raised to $60 from $48 at Deutsche Bank
06/18/20 Benchmark
Owens Corning price target raised to $63 from $51 at Benchmark
05/28/20 Jefferies
Owens Corning price target raised to $62 from $52 at Jefferies
OC Owens Corning
$55.06 /

-1.72 (-3.03%)

Initiation
Compass Point sees near and long term risks for Shift4 Payments, starts at Sell » 09:01
07/10/20
07/10
09:01
07/10/20
09:01
FOUR

Shift4 Payments

$44.69 /

-0.07 (-0.16%)

As previously reported,…

As previously reported, Compass Point analyst Michael Del Grosso initiated coverage of Shift4 Payments with a Sell rating and $35 price target. The analyst does not believe Shift4 is leading with a software-oriented approach when attempting to convert gateway merchants, but believes it is leading with price, leaving a near-term risk as he forecasts a material decline in the take rate by 2022 as a result of both mix-shift and aggressive pricing. While in the short-term the reliance on partners allows for superior operating expense leverage, it also presents a longer-term risk given the emergence of "PayFacs" and potential for more pricing pressure in the ISV/VAR channel in the hospitality industry, added Del Grosso.

ShowHide Related Items >><<
FOUR Shift4 Payments
$44.69 /

-0.07 (-0.16%)

FOUR Shift4 Payments
$44.69 /

-0.07 (-0.16%)

07/09/20 Compass Point
Shift4 Payments initiated with a Sell at Compass Point
07/01/20 Citi
Shift4 Payments initiated with a Neutral at Citi
06/30/20 Morgan Stanley
Shift4 Payments initiated with an Equal Weight at Morgan Stanley
06/30/20 SunTrust
Shift4 Payments initiated with a Buy at SunTrust
  • 05
    Jun
FOUR Shift4 Payments
$44.69 /

-0.07 (-0.16%)

FOUR Shift4 Payments
$44.69 /

-0.07 (-0.16%)

Recommendations
Masco price target raised to $53.50 from $38.50 at JPMorgan » 09:01
07/10/20
07/10
09:01
07/10/20
09:01
MAS

Masco

$49.69 /

-0.245 (-0.49%)

JPMorgan analyst Michael…

JPMorgan analyst Michael Rehaut raised the firm's price target on Masco to $53.50 from $38.50 and keeps a Neutral rating on the shares. Despite a strong rally since late March, the building products sector has not fully recovered its losses from the early days of the pandemic, Rehaut tells investors in a research note. The analyst increased estimates across the group to reflect an improved demand backdrop, "as even lagging subsectors have still likely witnessed monthly improvement."

ShowHide Related Items >><<
MAS Masco
$49.69 /

-0.245 (-0.49%)

MAS Masco
$49.69 /

-0.245 (-0.49%)

06/23/20 Deutsche Bank
Masco price target raised to $54 from $48 at Deutsche Bank
06/17/20 Baird
Masco price target raised to $54 from $45 at Baird
06/17/20 RBC Capital
Masco price target raised to $51 from $40 at RBC Capital
06/17/20 SunTrust
Masco price target raised to $58 from $52 at SunTrust
MAS Masco
$49.69 /

-0.245 (-0.49%)

MAS Masco
$49.69 /

-0.245 (-0.49%)

MAS Masco
$49.69 /

-0.245 (-0.49%)

Recommendations
Jeld-Wen price target raised to $18 from $12 at JPMorgan » 09:01
07/10/20
07/10
09:01
07/10/20
09:01
JELD

Jeld-Wen

$16.39 /

-0.28 (-1.68%)

JPMorgan analyst Michael…

JPMorgan analyst Michael Rehaut raised the firm's price target on Jeld-Wen to $18 from $12 and keeps a Neutral rating on the shares. Despite a strong rally since late March, the building products sector has not fully recovered its losses from the early days of the pandemic, Rehaut tells investors in a research note. The analyst increased estimates across the group to reflect an improved demand backdrop, "as even lagging subsectors have still likely witnessed monthly improvement."

ShowHide Related Items >><<
JELD Jeld-Wen
$16.39 /

-0.28 (-1.68%)

JELD Jeld-Wen
$16.39 /

-0.28 (-1.68%)

06/18/20 Benchmark
Jeld-Wen price target raised to $18 from $14 at Benchmark
05/27/20 Credit Suisse
Jeld-Wen initiated with an Underperform at Credit Suisse
04/27/20 B. Riley FBR
Jeld-Wen price target lowered to $11 from $14 at B. Riley FBR
04/16/20 Baird
Jeld-Wen downgraded to Neutral at Baird
JELD Jeld-Wen
$16.39 /

-0.28 (-1.68%)

Recommendations
Domino's Pizza price target raised to $375 from $350 at MKM Partners » 09:00
07/10/20
07/10
09:00
07/10/20
09:00
DPZ

Domino's Pizza

$385.60 /

+1.73 (+0.45%)

MKM Partners analyst…

MKM Partners analyst Brett Levy raised the firm's price target on Domino's Pizza to $375 from $350 but keeps a Neutral rating on the shares ahead of its Q2 earnings next week. The analyst notes that the company's early second quarter sales trends were robust, with an increase of 14% and 1% in domestic and international comps, though "on paper", the recent run-up in stock could create an opportunity for a potential reversion to the mean.

ShowHide Related Items >><<
DPZ Domino's Pizza
$385.60 /

+1.73 (+0.45%)

DPZ Domino's Pizza
$385.60 /

+1.73 (+0.45%)

07/10/20 Oppenheimer
Domino's Pizza price target raised to $425 from $405 at Oppenheimer
07/06/20 OTR Global
Domino's Pizza upgraded to Positive from Mixed at OTR Global
06/26/20 Stephens
Papa John's price target raised to $94 from $83 at Stephens
06/15/20 Longbow
Domino's domestic same-store sales holding up as dine-in reopens, says Longbow
DPZ Domino's Pizza
$385.60 /

+1.73 (+0.45%)

DPZ Domino's Pizza
$385.60 /

+1.73 (+0.45%)

DPZ Domino's Pizza
$385.60 /

+1.73 (+0.45%)

Recommendations
Fortune Brands price target raised to $74 from $60 at JPMorgan » 09:00
07/10/20
07/10
09:00
07/10/20
09:00
FBHS

Fortune Brands

$64.15 /

-0.965 (-1.48%)

JPMorgan analyst Michael…

JPMorgan analyst Michael Rehaut raised the firm's price target on Fortune Brands Home and Security to $74 from $60 and keeps an Overweight rating on the shares. Despite a strong rally since late March, the building products sector has not fully recovered its losses from the early days of the pandemic, Rehaut tells investors in a research note. The analyst increased estimates across the group to reflect an improved demand backdrop, "as even lagging subsectors have still likely witnessed monthly improvement."

ShowHide Related Items >><<
FBHS Fortune Brands
$64.15 /

-0.965 (-1.48%)

07/08/20 Wells Fargo
Fortune Brands price target raised to $67 from $52 at Wells Fargo
06/26/20 RBC Capital
Fortune Brands downgraded to Sector Perform from Outperform at RBC Capital
06/26/20 RBC Capital
Fortune Brands downgraded to Sector Perform from Outperform at RBC Capital
06/23/20 Deutsche Bank
Fortune Brands price target raised to $68 from $60 at Deutsche Bank
FBHS Fortune Brands
$64.15 /

-0.965 (-1.48%)

FBHS Fortune Brands
$64.15 /

-0.965 (-1.48%)

FBHS Fortune Brands
$64.15 /

-0.965 (-1.48%)

Recommendations
Cloudflare price target raised to $52 from $30 at JPMorgan » 08:59
07/10/20
07/10
08:59
07/10/20
08:59
NET

Cloudflare

$39.71 /

+1.305 (+3.40%)

JPMorgan analyst Sterling…

JPMorgan analyst Sterling Auty raised the firm's price target on Cloudflare to $52 from $30 and keeps an Overweight rating on the shares. The traction Cloudflare is seeing in its product portfolio "appears to be gaining steam through the current environment," Auty tells investors in a research note. Further, the analyst expects the company to convert its free Teams offering over to a paid solution in the coming quarters, which he says has the potential of generating "additional revenue tailwinds." Auty sees "ample upside opportunity" to the revenue results over the next several years to generate an attractive free cash flow profile that "propels the stock" to his price target.

ShowHide Related Items >><<
NET Cloudflare
$39.71 /

+1.305 (+3.40%)

NET Cloudflare
$39.71 /

+1.305 (+3.40%)

07/06/20 Piper Sandler
Cloudflare price target raised to $41 from $29 at Piper Sandler
06/24/20 Goldman Sachs
Cloudflare price target raised to $39 from $27 at Goldman Sachs
06/18/20 Morgan Stanley
Morgan Stanley ups Cloudflare to Equal Weight on security architecture changes
06/18/20 Morgan Stanley
Zscaler upgraded to Equal Weight from Underweight at Morgan Stanley
NET Cloudflare
$39.71 /

+1.305 (+3.40%)

  • 13
    Sep
NET Cloudflare
$39.71 /

+1.305 (+3.40%)

NET Cloudflare
$39.71 /

+1.305 (+3.40%)

NET Cloudflare
$39.71 /

+1.305 (+3.40%)

Recommendations
Akamai price target raised to $122 from $110 at JPMorgan » 08:56
07/10/20
07/10
08:56
07/10/20
08:56
AKAM

Akamai

$114.22 /

+1.47 (+1.30%)

JPMorgan analyst Sterling…

JPMorgan analyst Sterling Auty raised the firm's price target on Akamai to $122 from $110 and keeps an Overweight rating on the shares. States have started to open back up, but it is going slower than what was was factored into Akamai's guidance, and that could mean better than anticipated traffic again in June, Auty tells investors in a research note. The analyst estimates this will be more than enough to offset the concerns management outlined about the 16% of revenue in e-commerce areas that were expected to feel pressure because of ties to brick and mortar franchises.

ShowHide Related Items >><<
AKAM Akamai
$114.22 /

+1.47 (+1.30%)

AKAM Akamai
$114.22 /

+1.47 (+1.30%)

07/02/20 Cowen
Akamai upgraded to Outperform at Cowen
07/02/20 Cowen
Akamai upgraded to Outperform from Market Perform at Cowen
06/24/20 Raymond James
Amazon live TV would further differentiate Prime Video, says Raymond James
06/24/20 Goldman Sachs
Akamai price target raised to $107 from $102 at Goldman Sachs
AKAM Akamai
$114.22 /

+1.47 (+1.30%)

AKAM Akamai
$114.22 /

+1.47 (+1.30%)

AKAM Akamai
$114.22 /

+1.47 (+1.30%)

AKAM Akamai
$114.22 /

+1.47 (+1.30%)

Options
Notable open interest changes for July 10th » 08:55
07/10/20
07/10
08:55
07/10/20
08:55
BAC

Bank of America

$22.78 /

-0.33 (-1.43%)

, PCG

PG&E

$8.60 /

-0.185 (-2.11%)

, NIO

NIO Inc.

$14.59 /

+1.72 (+13.36%)

, BABA

Alibaba

$261.57 /

+3.94 (+1.53%)

Thursday's total…

Thursday's total option volume of 29.8 million contracts resulted in net open interest growth of 3.60 million calls and 2.81 million puts. Bank of America (BAC), PG&E (PCG), NIO (NIO) and Alibaba (BABA) saw the greatest growth. Top five new positions opened include 30k PG&E (PCG) Aug-20 10 calls, 29k PG&E (PCG) Aug-20 12 calls, 29k PG&E (PCG) Aug-20 8 puts, 27k Snap Inc. (SNAP) Jul-20 24 calls and 22k Sabre (SABR) Aug-20 9 puts.

ShowHide Related Items >><<
PCG PG&E
$8.60 /

-0.185 (-2.11%)

NIO NIO Inc.
$14.59 /

+1.72 (+13.36%)

BAC Bank of America
$22.78 /

-0.33 (-1.43%)

BABA Alibaba
$261.57 /

+3.94 (+1.53%)

BAC Bank of America
$22.78 /

-0.33 (-1.43%)

07/09/20 DA Davidson
Bank of America downgraded to Neutral from Buy at DA Davidson
07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Seaport Global
Bank of America initiated with a Neutral at Seaport Global
07/07/20 Societe Generale
Societe Generale upgrades BofA, Citi to Buy on 'path to respectability'
PCG PG&E
$8.60 /

-0.185 (-2.11%)

07/09/20 Mizuho
PG&E trading at 56% price-to-earnings discount, says Mizuho
06/24/20 Vertical Research
PG&E initiated with a Buy at Vertical Research
06/23/20 Seaport Global
PG&E initiated with a Neutral at Seaport Global
06/10/20 Barclays
PG&E price target raised to $16 from $15 at Barclays
NIO NIO Inc.
$14.59 /

+1.72 (+13.36%)

06/24/20
Fly Intel: Top five analyst downgrades
06/24/20 Goldman Sachs
NIO Inc. downgraded to Neutral from Buy at Goldman Sachs
06/09/20 86 Research
NIO Inc. initiated with a Sell at 86 Research
06/02/20 Goldman Sachs
NIO Inc. upgraded to Buy from Neutral at Goldman Sachs
BABA Alibaba
$261.57 /

+3.94 (+1.53%)

07/09/20
Fly Intel: Top five analyst initiations
07/09/20 Needham
Alibaba initiated with a Buy at Needham
06/19/20 Barclays
Alibaba price target raised to $270 from $260 at Barclays
06/19/20 Morgan Stanley
6.18 promotion in China released pent-up buying demand, says Morgan Stanley
PCG PG&E
$8.60 /

-0.185 (-2.11%)

NIO NIO Inc.
$14.59 /

+1.72 (+13.36%)

BAC Bank of America
$22.78 /

-0.33 (-1.43%)

BABA Alibaba
$261.57 /

+3.94 (+1.53%)

  • 26
    Jun
  • 11
    Jun
PCG PG&E
$8.60 /

-0.185 (-2.11%)

NIO NIO Inc.
$14.59 /

+1.72 (+13.36%)

BAC Bank of America
$22.78 /

-0.33 (-1.43%)

BABA Alibaba
$261.57 /

+3.94 (+1.53%)

PCG PG&E
$8.60 /

-0.185 (-2.11%)

NIO NIO Inc.
$14.59 /

+1.72 (+13.36%)

BAC Bank of America
$22.78 /

-0.33 (-1.43%)

BABA Alibaba
$261.57 /

+3.94 (+1.53%)

PCG PG&E
$8.60 /

-0.185 (-2.11%)

NIO NIO Inc.
$14.59 /

+1.72 (+13.36%)

BAC Bank of America
$22.78 /

-0.33 (-1.43%)

BABA Alibaba
$261.57 /

+3.94 (+1.53%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.